M&A / Acquisition · Africa · Announced 21 Oct 2026
Laprophan → Polymedic
M&A / Acquisition deal between Laprophan (Morocco) and Polymedic (Morocco), announced 21 Oct 2026.
Parties: Laprophan (Morocco) → Polymedic (Morocco)
- Deal type
- M&A / Acquisition
- Value
- Not stated
- Territory
- Morocco
- Therapeutic area
- Multi-therapy
- Asset
- 100% of CIH, parent company of laboratory Polymedic — portfolio, production capacity and distribution network
- Announced
- 21 Oct 2026
Our analysis
Why this matters
Morocco's most active pharmaceutical consolidator just made its fourth acquisition in three years. Laprophan announced on 21 October 2026 the acquisition of 100% of Corporate Investment Holding (CIH), the parent of laboratory Polymedic — the deal is signed but explicitly conditional on approval by Morocco's Competition Council. For CEOs: North African consolidation has moved from opportunistic to programmatic. For BD: Laprophan's acquisition sequence is a template — roll up fragmented local labs, then use a European bridgehead for export.
The full analysis is free to read with a work email on this page.
Source: SantéMag